Myriad Genetics (NASDAQ:MYGN) had its target price raised by Leerink Swann from $33.00 to $35.00 in a report released on Wednesday. They currently have a market perform rating on the stock. Leerink Swann also issued estimates for Myriad Genetics’ Q3 2018 earnings at $0.27 EPS, Q4 2018 earnings at $0.30 EPS, FY2018 earnings at $1.14 EPS, Q1 2019 earnings at $0.29 EPS, Q2 2019 earnings at $0.29 EPS, Q3 2019 earnings at $0.30 EPS, Q4 2019 earnings at $0.33 EPS and FY2019 earnings at $1.20 EPS.

MYGN has been the subject of a number of other reports. BTIG Research started coverage on Myriad Genetics in a research note on Friday, January 5th. They issued a buy rating and a $41.00 target price for the company. Barclays restated a hold rating and issued a $30.00 target price on shares of Myriad Genetics in a research note on Monday, January 8th. Zacks Investment Research upgraded Myriad Genetics from a hold rating to a strong-buy rating and set a $42.00 target price for the company in a research note on Tuesday, October 17th. Goldman Sachs Group started coverage on Myriad Genetics in a research note on Monday, January 29th. They issued a sell rating and a $32.00 target price for the company. Finally, ValuEngine upgraded Myriad Genetics from a hold rating to a buy rating in a research note on Friday, November 10th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Myriad Genetics currently has a consensus rating of Hold and a consensus target price of $31.42.

Shares of Myriad Genetics (NASDAQ:MYGN) opened at $32.96 on Wednesday. The company has a quick ratio of 2.06, a current ratio of 2.05 and a debt-to-equity ratio of 0.05. Myriad Genetics has a fifty-two week low of $15.71 and a fifty-two week high of $41.57. The firm has a market capitalization of $2,278.52, a PE ratio of 17.82, a P/E/G ratio of 2.41 and a beta of 0.32.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, February 6th. The company reported $0.31 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.07. Myriad Genetics had a return on equity of 9.59% and a net margin of 16.67%. The company had revenue of $194.00 million during the quarter, compared to the consensus estimate of $188.72 million. During the same period in the previous year, the firm posted $0.26 earnings per share. Myriad Genetics’s quarterly revenue was down 1.3% compared to the same quarter last year. equities analysts anticipate that Myriad Genetics will post 1.15 EPS for the current year.

In other news, insider Alexander Ford sold 3,031 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $31.64, for a total transaction of $95,900.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Heinrich Dreismann sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $33.50, for a total value of $201,000.00. Following the transaction, the director now owns 33,743 shares of the company’s stock, valued at $1,130,390.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,064 shares of company stock valued at $2,679,097. Insiders own 6.70% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Myriad Genetics by 1.5% during the fourth quarter. BlackRock Inc. now owns 10,066,753 shares of the company’s stock worth $345,743,000 after buying an additional 150,003 shares during the period. Vanguard Group Inc. lifted its position in Myriad Genetics by 0.9% in the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock worth $162,992,000 after purchasing an additional 56,708 shares during the period. Dimensional Fund Advisors LP lifted its position in Myriad Genetics by 4.4% in the third quarter. Dimensional Fund Advisors LP now owns 3,580,081 shares of the company’s stock worth $129,527,000 after purchasing an additional 149,865 shares during the period. Acadian Asset Management LLC lifted its position in Myriad Genetics by 18.4% in the fourth quarter. Acadian Asset Management LLC now owns 2,205,297 shares of the company’s stock worth $75,743,000 after purchasing an additional 343,196 shares during the period. Finally, Northern Trust Corp lifted its position in Myriad Genetics by 31.1% in the second quarter. Northern Trust Corp now owns 1,292,588 shares of the company’s stock worth $33,400,000 after purchasing an additional 306,276 shares during the period.

TRADEMARK VIOLATION WARNING: “Myriad Genetics (MYGN) Price Target Raised to $35.00 at Leerink Swann” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/10/myriad-genetics-mygn-price-target-raised-to-35-00-at-leerink-swann.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.